BioCentury | Dec 5, 2020
Management Tracks

CureVac hires GSK Vaccines veteran Blanc as CBO and chief commercial officer; plus moves at Spero, 4D, Transgene, Achilles and Datavant

...of the Institute of Metabolic Disease at the Baylor Research Institute; and Kim was CMO at ViewPoint Therapeutics Inc....
...Therapeutics Inc. Transgene S.A. Achilles Therapeutics Ltd. Datavant Inc. GlaxoSmithKline plc Millendo Therapeutics Inc. Xoc Pharmaceuticals Inc. Baylor Scott & White Research Institute ViewPoint Therapeutics Inc. Institut...
BioCentury | May 3, 2018
Company News

Management tracks: Achillion, Sangamo

...and CEO at Tech City UK, which is now Tech Nation (London, U.K.). Ophthalmic company ViewPoint Therapeutics Inc....
BioCentury | Mar 15, 2018
Emerging Company Profile

Stabilizing damaged goods

...has not disclosed whether it has filed any patent applications. At least one other company, ViewPoint Therapeutics Inc....
...GWPH), Cambridge, U.K. Methuselah Health Inc., Wilmington, Del. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan ViewPoint Therapeutics Inc....
BioCentury | Mar 9, 2018
Financial News

Viewpoint raises $35M series B

...TPG's Heath Lukatch and Novo's Peter Moldt joined ViewPoint's board. ViewPoint Therapeutics Inc., San Francisco, Calif. Paul Bonanos VP1-001 ViewPoint Therapeutics Inc....
BioCentury | Mar 5, 2018
Financial News

Ophthalmic play ViewPoint raises $35M series B

...Innovations, Nov. 12, 2015) . TPG's Heath Lukatch and Novo's Peter Moldt joined ViewPoint's board. Paul Bonanos VP1-001 ViewPoint Therapeutics Inc....
BioCentury | May 9, 2016
Financial News

ViewPoint Therapeutics completes venture financing

ViewPoint Therapeutics , San Francisco, Calif. Business: Ophthalmic Date completed: 2016-05-05 Type: Venture financing Raised: $4 million Investors: Mission Bay Capital LLC; Lagunita BioSciences; Biotechnology Value Fund; University of Michigan ; Asset Management; individual investors WIR...
BioCentury | May 6, 2016
Financial News

ViewPoint raises $4M in series A

ViewPoint Therapeutics Inc. (San Francisco, Calif.) raised $4 million in a series A round co-led by Mission Bay Capital and Lagunita BioSciences. Biotechnology Value Fund, the University of Michigan MINTS initiative, Asset Management Ventures and...
BioCentury | Nov 12, 2015
Product R&D

Crystallin-clear ViewPoint

...value with molecular chaperones. After finding a compound that clears up cataracts, the team formed ViewPoint Therapeutics Inc....
...Calif. University of California San Francisco, San Francisco, Calif. University of Michigan, Ann Arbor, Mich. ViewPoint Therapeutics Inc....
BioCentury | Nov 12, 2015
Distillery Therapeutics

Therapeutics: Crystallin α B (CRYAB; HSPB5)

...from cataract patients, the lead compound increased total protein solubility. Next steps in collaboration with ViewPoint Therapeutics Inc....
...page 8) TARGET/MARKER/PATHWAY: Crystallin α B (CRYAB; HSPB5 ) LICENSING STATUS: Patented; exclusively optioned to ViewPoint Therapeutics Inc....
Items per page:
1 - 9 of 9
BioCentury | Dec 5, 2020
Management Tracks

CureVac hires GSK Vaccines veteran Blanc as CBO and chief commercial officer; plus moves at Spero, 4D, Transgene, Achilles and Datavant

...of the Institute of Metabolic Disease at the Baylor Research Institute; and Kim was CMO at ViewPoint Therapeutics Inc....
...Therapeutics Inc. Transgene S.A. Achilles Therapeutics Ltd. Datavant Inc. GlaxoSmithKline plc Millendo Therapeutics Inc. Xoc Pharmaceuticals Inc. Baylor Scott & White Research Institute ViewPoint Therapeutics Inc. Institut...
BioCentury | May 3, 2018
Company News

Management tracks: Achillion, Sangamo

...and CEO at Tech City UK, which is now Tech Nation (London, U.K.). Ophthalmic company ViewPoint Therapeutics Inc....
BioCentury | Mar 15, 2018
Emerging Company Profile

Stabilizing damaged goods

...has not disclosed whether it has filed any patent applications. At least one other company, ViewPoint Therapeutics Inc....
...GWPH), Cambridge, U.K. Methuselah Health Inc., Wilmington, Del. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan ViewPoint Therapeutics Inc....
BioCentury | Mar 9, 2018
Financial News

Viewpoint raises $35M series B

...TPG's Heath Lukatch and Novo's Peter Moldt joined ViewPoint's board. ViewPoint Therapeutics Inc., San Francisco, Calif. Paul Bonanos VP1-001 ViewPoint Therapeutics Inc....
BioCentury | Mar 5, 2018
Financial News

Ophthalmic play ViewPoint raises $35M series B

...Innovations, Nov. 12, 2015) . TPG's Heath Lukatch and Novo's Peter Moldt joined ViewPoint's board. Paul Bonanos VP1-001 ViewPoint Therapeutics Inc....
BioCentury | May 9, 2016
Financial News

ViewPoint Therapeutics completes venture financing

ViewPoint Therapeutics , San Francisco, Calif. Business: Ophthalmic Date completed: 2016-05-05 Type: Venture financing Raised: $4 million Investors: Mission Bay Capital LLC; Lagunita BioSciences; Biotechnology Value Fund; University of Michigan ; Asset Management; individual investors WIR...
BioCentury | May 6, 2016
Financial News

ViewPoint raises $4M in series A

ViewPoint Therapeutics Inc. (San Francisco, Calif.) raised $4 million in a series A round co-led by Mission Bay Capital and Lagunita BioSciences. Biotechnology Value Fund, the University of Michigan MINTS initiative, Asset Management Ventures and...
BioCentury | Nov 12, 2015
Product R&D

Crystallin-clear ViewPoint

...value with molecular chaperones. After finding a compound that clears up cataracts, the team formed ViewPoint Therapeutics Inc....
...Calif. University of California San Francisco, San Francisco, Calif. University of Michigan, Ann Arbor, Mich. ViewPoint Therapeutics Inc....
BioCentury | Nov 12, 2015
Distillery Therapeutics

Therapeutics: Crystallin α B (CRYAB; HSPB5)

...from cataract patients, the lead compound increased total protein solubility. Next steps in collaboration with ViewPoint Therapeutics Inc....
...page 8) TARGET/MARKER/PATHWAY: Crystallin α B (CRYAB; HSPB5 ) LICENSING STATUS: Patented; exclusively optioned to ViewPoint Therapeutics Inc....
Items per page:
1 - 9 of 9